Form 4: Chimerix Director Martha J. Demski Reports Disposal of Shares and Options Following Merger with Jazz Pharmaceuticals

Following the merger of Chimerix with Jazz Pharmaceuticals, director Martha J. Demski reported the disposal of common stock and stock options as per the merger agreement.

Summary

• Martha J. Demski, a director of Chimerix, filed a Form 4 to report changes in beneficial ownership following the merger of Chimerix with Jazz Pharmaceuticals.
• The merger was executed under an agreement where Jazz Pharmaceuticals acquired Chimerix for $8.55 per share.
• Demski disposed of 72,055 shares of common stock at $8.55 per share as a result of the merger.
• Additionally, Demski's employee stock options were either cashed out (for 'in the money' options) or cancelled (for options with an exercise price higher than the offer price) according to the merger agreement.
• The filing details the disposal of various employee stock options with different exercise prices and expiration dates.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports the execution of a previously announced merger. There are no indications of unexpected positive or negative outcomes.

Future Outlook

The document does not contain any forward-looking statements beyond the completion of the merger.

Management Comments

• The foregoing descriptions in the footnotes to this Form 4 are qualified in their entirety by reference to the terms of the Merger Agreement.
• In the event of any conflict between the descriptions above and the terms set forth in the Merger Agreement, the terms set forth in the Merger Agreement shall control.

Industry Context

This announcement reflects the ongoing consolidation within the pharmaceutical industry, where larger companies like Jazz Pharmaceuticals acquire smaller entities like Chimerix to expand their product portfolios and pipelines.

Comparison to Industry Standards

• Merger and acquisition (M&A) activity is common in the pharmaceutical industry, with companies like Pfizer, Novartis, and Roche frequently engaging in similar transactions to acquire promising drug candidates or technologies.
• The valuation of $8.55 per share for Chimerix reflects market conditions and the company's perceived value based on its assets and future prospects, which is typical in such deals.
• The treatment of stock options in the merger agreement, where 'in the money' options are cashed out and others are cancelled, is a standard practice in M&A transactions to ensure fair compensation to option holders.

Stakeholder Impact

• Shareholders received $8.55 per share as a result of the merger.
• Option holders with 'in the money' options received a cash payment, while others had their options cancelled.
• Chimerix became an indirect wholly-owned subsidiary of Jazz Pharmaceuticals.

Key Dates

Keywords

Form 4, Chimerix, Jazz Pharmaceuticals, Merger, Stock Options, Beneficial Ownership, Director, Demski, CMRX